Pfizer’s Commitment to Pfizer’s Commitment to the Advance Market the Advance Market Commitment (AMC)Commitment (AMC)

Pfizer Committed to Reducing Pfizer Committed to Reducing Childhood Mortality (MDG 4)Childhood Mortality (MDG 4)

• Partnership with UNICEF, the GAVI Alliance and the governments of Rwanda and The Gambia to donate more than 3 million doses of Prevenar* for the period 2009-2010. Both countries will transition to the AMC this year

• Leading the fight against PD in China where one in every four children is a carrier of the bacteria – Jointly, with the Chinese Medical Association and the China Preventative Medicine Association, developed and sponsored the launch of “Guidelines on Control Techniques of Children’s Pneumococcal Disease”

• 2008 economic analysis of infant inoculation with Prevenar in Latin America and the Caribbean estimated that the introduction of the vaccine had the potential to reduce childhood mortality and be highly cost effective

• 2010 Poland Study on the use of Prevenar shows significant fall in the average pneumonia admission rates

Source: Innovative Partnerships – Progress Toward Achieving the Millennium Development Goals - Pfizer

*Trademark

Faster Access for Developing CountriesFaster Access for Developing CountriesGAVI and the Advance Market Commitment GAVI and the Advance Market Commitment (AMC) Program(AMC) Program

• AMC supply agreement announced March 2010• 19 countries are approved by GAVI for AMC

program• WHO granted prequalification for Prevenar 13*

Single Dose Vial (SDV) August 2010• AMC Independent Assessment Committee

approved Prevenar 13 as eligible for purchase August 2010

• First shipment to UNICEF through AMC executed on 29 October 2010

• Yemen, Sierra Leone, Nicaragua, Honduras, Guyana, Mali and DR Congo initiated NIP programs with Prevenar 13 via the AMC

Prevnar 13 is not approved for the prevention of pneumonia caused by vaccine serotypes in the United States.

*Trademark

Pfizer’s Commitments to the AMCPfizer’s Commitments to the AMC• Deliver ~30 million doses of Prevenar 13* annually

beginning 2013

• Vaccine production plan (capacity expansion plan)– Capital investments– Process improvements– Efficiency measures across supply network

• Develop a preserved multi-dose vial specifically for AMC

– 4-dose vial – subject to prequalification requirements– Support countries with difficult infrastructures

Doses (millions) 2010 2011 2012 2013+

Pfizer 6 20 20 30

GSK 1.2 4.2 30 30

*Trademark